# EDGAR Filing Document

**Accession Number:** 0001959708
**File Stem:** 0001062993-26-001956
**Filing Date:** 2026-4
**Character Count:** 3040
**Document Hash:** dcc4634bf7e928539aa04264353d9051
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-26-001956.hdr.sgml**: 20260413

**ACCESSION NUMBER**: 0001062993-26-001956

**CONFORMED SUBMISSION TYPE**: 1-A-W

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260413

**DATE AS OF CHANGE**: 20260413

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Algernon Neuroscience Inc.
- **CENTRAL INDEX KEY:** 0001959708
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 785435413
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0831

**FILING VALUES:**
- **FORM TYPE:** 1-A-W
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 024-12558
- **FILM NUMBER:** 26858093

**BUSINESS ADDRESS:**
- **STREET 1:** 400-601 WEST BROADWAY
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V5Z 4C2
- **BUSINESS PHONE:** (604) 398-4175

**MAIL ADDRESS:**
- **STREET 1:** 400-601 WEST BROADWAY
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V5Z 4C2

------

**ALGERNON NEUROSCIENCE INC.**

**400 - 601 West Broadway**

**Vancouver, British Columbia, Canada** 

**V5Z 4C2**

April 13, 2026

<u>VIA EDGAR</u>

United States Securities and Exchange Commission<br>Division of Corporation Finance<br>Office of Life Sciences<br>100 F Street, N.E. Washington, D.C. 20549

Dear Sirs/Mesdames:

**Re: Algernon NeuroScience Inc.**<br>**Withdrawal of Offering Statement on Form 1-A**<br>**File No. 024-12558**

Pursuant to Rule 259 of Regulation A promulgated pursuant to the Securities Act of 1933, as amended (the "**Securities Act**"), Algernon NeuroScience Inc. (the "**Company**") respectfully requests the withdrawal of its Offering Statement on Form 1-A (File No. 024-12558), together with all amendments and exhibits thereto (collectively, the "**Offering Statement**"), first filed with the Securities and Exchange Commission (the "**Commission**") on January 24, 2025. The Offering Statement relates to the public offering of the Company's Common Stock (the "Common Stock").

The Company is requesting the consent of the Commission to the withdrawal of the Offering Statement because the Company has determined it is not in the best interest of the Company to continue with this Offering Statement. No Common Stock has been sold in this offering.

Accordingly, the Company respectfully requests that the Commission issues an order granting the withdrawal of the Offering Statement effective as of the date hereof or at the earliest practicable date hereafter.

Please send a copy of the written order granting withdrawal of the Registration Statement to the undersigned at Algernon NeuroScience Inc., 400 - 601 West Broadway, Vancouver, British Columbia, Canada V5Z 4C2.

If you have any further questions regarding this request for withdrawal, or if you require any additional information, please contact James Kinley, the Company's Chief Financial Officer.

------

---

| |
|:---|
| Sincerely, |
| **Algernon NeuroSceince Inc.** |
| <u>*/s/ James Kinley*</u> |
| James Kinley |
| Chief Financial Officer |

---

------